The U.S. Food and Drug Administration (FDA) approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) on February 28, 2019. This approval designates Herceptin Hylecta as a Type 5 - New Formulation or New Manufacturer product, sponsored by Genentech Inc.
Background
Herceptin Hylecta is a combination product involving trastuzumab and hyaluronidase-oysk. The FDA's classification of this approval as Type 5 - New Formulation or New Manufacturer indicates a significant change in how the drug is presented or produced compared to existing versions. A "new formulation" typically refers to a different dosage form, strength, route of administration, or excipients, while a "new manufacturer" indicates a different entity producing the drug. This specific approval means that a new version of the established therapeutic agent, trastuzumab, is now available in combination with hyaluronidase-oysk, under a new manufacturing or formulation process.
What this means
The FDA approval of Herceptin Hylecta as a Type 5 - New Formulation or New Manufacturer product expands the options for patients and healthcare providers. Approvals of this nature can lead to several practical implications, such as potentially offering different administration methods, improved patient convenience, or enhanced manufacturing efficiencies. While specific details regarding the advantages of this particular new formulation are not provided in the approval data, such classifications generally aim to improve aspects of drug delivery or accessibility. This approval ensures continued access to trastuzumab-based therapy through a newly approved product from Genentech Inc.
Source
The information regarding this approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for Biologics License Application (BLA) 761106 for Herceptin Hylecta was granted on February 28, 2019, and is publicly accessible on accessdata.fda.gov.